The global market for blood gas monitoring systems is expected to grow 6.1% annually to reach $4.9bn in 2023, driven by the rising prevalence of chronic diseases, the aging population, and pressure on medical device makers to introduce smart devices that improve outcomes while reducing cost of care.

This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.

Medtech Insight talked to GreyBird Ventures founder Tom Miller about his investment philosophy, ethical filter in selecting diagnostics-focused start-ups, the future of diagnostics such as at-home home-testing and AI, and his life-long passion for motocross racing.